Everstar Asset Management LLC Boosts Position in Pfizer Inc. (NYSE:PFE)

Everstar Asset Management LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 2.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 20,793 shares of the biopharmaceutical company’s stock after buying an additional 594 shares during the quarter. Everstar Asset Management LLC’s holdings in Pfizer were worth $552,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in PFE. Nordea Investment Management AB grew its position in shares of Pfizer by 36.1% in the fourth quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company’s stock valued at $108,002,000 after purchasing an additional 1,080,822 shares during the last quarter. Parsons Capital Management Inc. RI grew its holdings in Pfizer by 118.7% during the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company’s stock valued at $7,820,000 after buying an additional 159,984 shares during the last quarter. NFJ Investment Group LLC increased its position in Pfizer by 12.8% during the third quarter. NFJ Investment Group LLC now owns 384,571 shares of the biopharmaceutical company’s stock worth $11,129,000 after buying an additional 43,719 shares in the last quarter. Copley Financial Group Inc. acquired a new position in shares of Pfizer in the third quarter worth $577,000. Finally, Zacks Investment Management lifted its position in shares of Pfizer by 10.9% in the third quarter. Zacks Investment Management now owns 2,389,138 shares of the biopharmaceutical company’s stock valued at $69,142,000 after acquiring an additional 235,243 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Citigroup dropped their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Truist Financial reduced their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. UBS Group reduced their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Finally, Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, six have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Price Performance

PFE opened at $25.20 on Monday. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The firm has a market cap of $142.93 billion, a price-to-earnings ratio of 17.87, a PEG ratio of 0.64 and a beta of 0.61. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company has a fifty day simple moving average of $26.06 and a 200 day simple moving average of $26.90.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same period last year, the firm earned $0.10 earnings per share. The company’s revenue was up 24.7% on a year-over-year basis. Equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is owned by company insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.